Through differential screening of established human leukaemia cell lines, we have identified and molecularly cloned lymphopain, a novel cysteine proteinase of the papain family. Lymphopain exhibits a remarkably restricted cellular pattern of expression, being predominantly expressed in cytotoxic T-lymphocytes and natural killer cells. The human lymphopain locus maps to chromosome 11q13, encodes a polypeptide of 376 amino acids and is conserved in the mouse. Both human and murine forms appear more closely related to protozoan papainlike enzymes than to other mammalian members of the papain family. The cellular distribution of lymphopain expression, together with the functional demonstration of lymphopainassociated proteinase activity in vitro, is suggestive of a role for lymphopain in immune cell-mediated, cell killing.
Introduction
The papain family of cysteine peptidases (family C1, see Ref.
1 for review) has representatives in bacteria, viruses, plants and animals. Although the major features of these enzymes are clearly conserved, the family can be further divided into four distinct branches of a phylogenetic tree: the cathepsin B branch, the plant branch, a branch containing enzymes from protozoa, and the cathepsin L branch. 2 In mammals, some of the papain family enzymes, such as cathepsins B (EC 3.4.22.1), H (EC 3.4.22.16), L (EC 3.4.22.15), and dipeptidyl peptidase I (EC3.4.14.1) are found in many cell types as major components of the lysosomal protein degradation system, 3 though exceptionally, as in the case of bleomycin hydrolase, they are cytosolic. Other mammalian members of the family, such as cathepsin S (EC 3.4.22.27) and cathepsin K (EC 3.4.22.38) (also known as cathepsin O2), appear to have more specific functions in antigen processing, 4 and bone resorption, 5 respectively, and these functions are reflected in their distribution. We now report on a new mammalian cysteine peptidase of the papain family. This enzyme, which we have named lymphopain, was cloned as part of a differential screen aimed at isolating molecules which exhibit lineage-specific patterns of expression within the haemopoietic system. Surprisingly, lymphopain appears to be more closely related to the papain-like enzymes from protozoa than to mammalian papain-family members. The gene maps to 11q13 in humans and is conserved in the mouse. Lymphopain expression is largely restricted to the haemopoietic system and in particular to the T cell compartment where it is associated with cytotoxic T lymphocytes (CTL), and natural killer cells. This cellular distribution, together with the demonstration that lymphopain encodes a functional enzyme, leads us to speculate that lymphopain may play a role in CTL/NK cell-mediated cell killing. 
Results and discussion

Molecular cloning of lymphopain
Human leukaemia cell lines have provided an invaluable resource for the molecular analysis of the haemopoietic system. 6, 7 We have used two such lines which have different haemopoietic lineage affiliations in a differential screen aimed at identifying genes with lineage or stage-restricted patterns of gene expression within the haemopoietic system. One of these, namely KG-1a is thought to represent a haemopoietic progenitor cell with both lymphoid and myeloid potential. [8] [9] [10] The other, K562, is considered to represent a multimyeloid progenitor with erythroid, megakaryocytic and monocytic potential.
11 KG-1a mRNA was used to produce 32 P-labelled single stranded first strand cDNA which was hybridised in solution against an excess of K562 mRNA. Unhybridised cDNA was selected using hydroxyapatite chromatography and subjected to another round of hybridisation. The resulting material was used to probe a KG-1a cDNA library prepared in phage . Two hundred positively hybridising plaques were picked and rescreened at lower density. Positives from this screen were replica plated and duplicate filters screened with either KG-1a or K562 cDNA probes. Arrays of differential clones were subsequently screened with cDNA probes derived from a panel of lymphoid and myeloid leukaemia cell lines (KG-1, JM, KM3, U937 and ML1) and then used as probes on Northern blots of this same cell line panel. The three clones which appeared to be substantially more highly expressed in KG-1a and KG-1 than in the other cell lines tested were sequenced. Two of these corresponded to genes which are known: ISGF-3, initially described as an interferondependent transcription factor 12 and now known as STAT-1, and NK-4, 13 a gene expressed in activated natural killer cells and T cells. ISGF-3/STAT-1 and NK-4 are represented eight and 18 times, respectively, amongst the differential clones. The third differential clone, designated A17, was represented 14 times and did not appear in any of the sequence databases examined and was therefore selected for further analysis. A17 was named lymphopain (Lpn) to reflect its KG-1/KG-1a specificity, its sequence homology to papain-family proteinases and its amidase activity (see below).
Tissue distribution of lymphopain expression
The expression pattern of lymphopain was further examined by Northern blot analysis of normal human tissue mRNAs. The lymphopain probe detected a 1.3 kb mRNA which is highly expressed in spleen and peripheral blood leukocytes; low level expression is seen in the thymus and some other tissues (Figure 1a) . No expression of lymphopain was observed in either foetal liver or foetal spleen and little or no expression was seen in adult lung or liver samples ( Figure 1b) ; both of these tissues are rich in cysteine proteinases. No lymphopain
Figure 1
Northern blot analysis of lymphopain expression in human tissues. (a) Lanes contain 2 g of poly A + RNA isolated from the tissues indicated (Clontech). The membrane was rehybridised with GAPDH and globin probes to control for sample loading and blood cell contamination of tissues respectively. (b) Human foetal spleen, foetal liver and embryonic skin samples contain 2.5 g of total RNA. Adult lung and liver samples contain 0.6 g of poly A + RNA. The membrane was rehybridised with an actin probe to control for sample loading. (c) Lymphopain probing of human bone marrow (15 g) and KG-1 (15 g) samples; GAPDH probing provides a loading control. expression was observed in embryonic skin (Figure 1b) , foetal skin, adult skin, keratinocytes or sebocytes (not shown). Similarly lymphopain expression was not detected in breast cancer cells (T47D), neuroblastoma (IMR 32 ), hepatocellular carcinoma (HepG2), salivary gland carcinoma (HSG), undifferentiated embryonal carcinoma (T 2 Cl 3 ) or embryonal carcinoma cells induced to differentiate by retinoic acid treatment (not shown). High levels of lymphopain mRNA were however seen in adult primary bone marrow cells (Figure 1c) . Taken together these data are consistent with a primarily haemopoietic expression profile which was examined in more detail by subfractionating peripheral blood (Figure 2 ).
Expression of lymphopain in lymphocytes
Two different peripheral blood samples were analysed and in both cases lymphopain expression was associated with the lymphocyte-containing fractions 1 and 4 which contain 25% and 95% lymphocytes, respectively. These results are consistent with analysis of lymphopain expression in haemopoietic cell lines where no lymphopain expression was observed in K562 (CML in myeloid blast crisis), HL-60 (AML), ML-1 (AML), U937 (monocytic), or THP-1 (monocytic). Furthermore, the lymphopain signal observed in the lymphocyte fraction was substantially reduced by depletion of T-lymphocytes using erythroid cell rosetting (see Methods) and the human B cell lines that were tested (Nalm 6, KM3, REH, Daudi) were all negative for lymphopain mRNA (not shown). These data suggest a predominantly T-lymphocyte expression profile for lymphopain and peripheral T-lymphocytes were therefore subfractionated into CD4-and CD8-positive subsets using antibody-coated beads; the purity of these immunopurified populations was confirmed by FACS analysis (Figure 3a) . Northern blot analysis of lymphopain expression in these samples is shown in Figure 3b . The results are not immediately striking but suggest expression in both CD4-and CD8-positive cells, although expression in CD4-positive cells appears weaker. These data suggest that expression within T cells may be more complex than originally anticipated, a notion also supported by the low level expression seen in the thymus and the observation that lymphopain expression in T cell lines is variable (not shown). Expression in T cells and in
Figure 2
Northern blot analysis of lymphopain expression in fractionated peripheral blood from two normal individuals. Fraction 1, buffy coat; fraction 2, lymphocyte-depleted buffy coat lysed with NH 4 Cl to remove red blood cells; fraction 3, lymphocyte-depleted buffy coat without red cell depletion; fraction 4, mononuclear cells. The cellular composition of the different fractions was assessed by morphological analysis (see Methods). From left to right, lanes were loaded with approximately 4.0, 1.9, 2.7, 10, 3.7, 1.6, 3.8, 10, 10 g of total RNA and sample loading is controlled for by actin probing. Figure 3 Analysis of lymphopain expression in the lymphocyte compartment. Peripheral T-lymphocytes from two normal individuals (samples 1 and 2) were purified using anti-CD4 or anti-CD8 coated beads. The purity of the enriched (post column +ve) populations is shown in the FACS plots in (a). Total RNA from these populations was analysed by Northern blotting with lymphopain and actin control probes (b 
Analysis of lymphopain expression in lymphocytic leukaemias
Blood mononuclear cells from nine patients with a lymphoid malignancy were analysed. All cases had Ͼ90% leukaemic cells. The diagnosis was based on clinical features, cell morphology, immunophenotype and, when required, cytogenetics and/or analysis of the TCR chain gene configuration (see Table 1 ). Four of the T cell samples corresponded to large granular lymphocyte (LGL) leukaemia, a disease characterised by the clonal proliferation of cytotoxic and/or natural killer cells. Of these large granular lymphocyte leukaemias, two had a cytotoxic phenotype whose cells expressed CD8 and the natural killer marker CD16 (SM, NG), one was CD4 − CD8
− and expressed only natural killer cell markers (RO) and another had a CD4 + phenotype with coexpression of the natural killer marker CD56 and thus might represent the expansion of a very rare natural killer cell subset whose cells are CD4
+ . The other T cell samples analysed included a T cell prolymphocytic leukaemia (mature) and two T cell acute lymphoblastic leukaemias (immature), one was CD4 + whilst the other was CD8 + . The two cases with a B cell malignancy corresponded to an immature or common acute lymphoblastic leukaemia and to a mature B cell disease, a B cell chronic lymphocytic leukaemia.
Strong expression of lymphopain was only observed in the large granular lymphocytic leukaemia samples (RO, NG, HL and SM). Expression was probably not simply a function of the maturity of these samples, as lymphopain expression was not detected in a mature T cell prolymphocytic leukaemia sample (EJ). These data are consistent with the failure to uncategorically assign lymphopain expression to either CD4-or CD8-positive T cell subsets: the large granular cell leukaemias which express lymphopain are heterogeneous with regard to CD4 and CD8 expression and the clearly CD4 single-positive (EK) and CD8 single-positive (BN) acute lymphoblastic leukaemias do not express lymphopain. This large granular cell association of lymphopain expression is intriguing. This population of cells is associated with the natural killer cell compartment 14 and all the lymphopain-positive leukaemias express at least one of the granular/killer cell mar-kers, CD16, CD56 or CD57. Furthermore, the KG-1/KG-1a cells from which lymphopain was cloned appear to express a number of natural killer cell associated molecules and this is reflected in our cloning of NK-4 and ISGF-3/STAT-1 in our differential screen. Finally the expression of lymphopain is seen in the natural killer cell line NKL ( Figure 3C ). On the basis of these data we speculate that lymphopain may play a role in cytotoxic T and natural killer cells, most likely in cellmediated cell killing where both serine (granzyme) and cysteine (caspase/dipeptidyl peptidase I) proteinases have been shown to be involved.
Structure of the human lymphopain locus
Two strategies were taken to obtain a full length lymphopain coding region: (1) KG-1 cDNA libraries were PCR-amplified using internal primers from the lymphopain coding region together with primers to cloning vector sequences; (2) PCR screening of a human P1 genomic library with lymphopainspecific primers was undertaken. Both genomic and cDNA clones were sequenced and the results of this analysis, together with the predicted amino acid sequence are presented in Figure 4 . The human lymphopain gene is comprised of 10 exons distributed over a DNA interval of approximately 4 kb and is predicted to encode a translation product of 376 amino acids. Analysis of this predicted amino acid sequence identifies lymphopain as a member of the papain (C1) family of peptidases. 1 As with almost all members of this family, its cDNA encodes a putative signal peptide and propeptide, suggesting that it is a secreted protein, destined either for the extracellular milieu or the lysosomal/endosomal compartment. Transient transfection experiments in COS cells using a c-terminal epitope (myc) tagged Lpn cDNA have yielded inconclusive results with regard to determining the intracellular localisation of lymphopain (data not shown). While some evidence for lysosomal compartmentalisation has been obtained, the predominant pattern of staining is consistent with localisation to the endoplasmic reticulum. This may reflect the inability of COS cells to appropriately 'handle' ectopically expressed lymphopain or may result from cterminal processing problems with the myc-tag. Table 1 Immunophenotype of lymphoid leukaemias
Large granular lymphocyte leukaemia 1-SM
B cell malignancies 8-MK SmIg+ (lambda), CD79b+, FMC7+, CD10−, CD2− 9-BY TdT+, CD19+, CD10+, CD22+, CD56−, CD2− A marker was considered positive when over 90% of leukaemic cells expressed the antigen recognised by the monoclonal antibody. The level of T cell contamination in B cell diseases was 9% and 2% as assessed by the staining with CD2 and CD3. cyt, cytoplasmic positive but membrane negative.
Figure 4
Nucleotide sequence of the human lymphopain locus. The sequence is compiled from the analysis of cDNA and genomic clones. Coding regions are in upper case and flanking regions and intronic sequences are shown in lower case. Predicted amino acid translation of the coding regions is shown below the corresponding nucleotides. The probable final residue of the signal peptide and the first residue of the mature protein are underlined. The active site residues are italicised and underlined. These sequence data are available from GenBank under accession numbers: AF013611, AF015954.
Mapping and evolutionary conservation of lymphopain
The lymphopain gene was mapped to chromosome band 11q13 by FISH analysis (Figure 5a , see Methods). This chromosomal localisation was consistent with mapping data obtained by PCR analysis of a panel of monochromosomal human-rodent hybrids. Human-specific lymphopain signals were only seen in hybrid JICL4 which contains human chromosome 11 and hybrid HORL1 which contains both human chromosome 15 and the long (q) arm of human chromosome 11 ( Figure 5b and data not shown). In addition to the product corresponding to human lymphopain, the lymphopain primers used detected additional bands in the hybrid panel; a band of 1.4 kb in the human-mouse hybrids and a band of 1.3 kb in the human-hamster hybrids suggesting that lymphopain-like sequences may be conserved in rodents (Figure 5b ). This notion was further supported by Southern blot analysis of murine genomic DNA using a human lymphopain cDNA clone as a probe ( Figure 5c ); this analysis also raises the possibility that lymphopain-related sequences may also be presented in the pig genome. The PCR product observed in the mouse was sequenced and the remaining murine lymphopain coding region was obtained using 5Ј and 3Ј RACE analysis of murine spleen mRNA. The sequence of these PCR products was confirmed by DNA sequencing of subsequently isolated murine genomic clones (J Brown and T Enver, unpublished). Human and mouse lymphopain coding sequences are 76% identical at the nucleotide level. An alignment of human and mouse predicted amino acid sequences is shown in Figure 5d . The pre-pro-proteins display 69% identity and 79% similarity; the predicted mature enzymes
Figure 5
Chromosomal localisation and evolutionary conservation. (a) Mapping the human lymphopain locus by FISH (fluorescence in situ hybridisation). The X-chromosome control probe is pseudocoloured in red and the lymphopain probe in green. (b) Chromosome mapping of the human lymphopain locus by PCR analysis of human-rodent monochromosomal hybrids. Typical data from the analysis of the hybrid panel are shown. The rodent origin of the individual hybrids is indicated; Ha, hamster; Mo, mouse. PCR using human lymphopain-derived oligomers (fwd: 5Ј-TGAGTTTGGGGTGACTCCATTC-3Ј, rev: 5Ј-CAAAACCCACCAGCAGGACAGA-3Ј) amplifies a 1.8 kb product corresponding to the human lymphopain locus as well as 1.4 kb and 1.3 kb products in mouse-and hamster-derived hybrids, respectively. These products were Southern blotted using the 32 P-labelled fwd primer as a probe (upper panel). The lower panel shows hybridisation of the same filter using a human lymphopain-specific oligomer (5Ј-GGTCTCTATGTTGCCTGCCGCT-3Ј), internal to the amplified product, as a probe. (c) Zoo-blot analysis. Genomic DNA from the sources indicated was restricted with EcoRI (E) or BamHI (B) and Southern blotted using a full length human lymphopain cDNA probe. Numbers on the right are in kilobase pairs and represent the migration of the -HindIII molecular weight marker. For the exposure shown the filter was washed at a stringency of 1 × SSC at 50°C. (d) Multiple amino acid alignment of human and murine lymphopain with CP5 from Dictyostelium discoideum, papain from Carica papaya, cruzipain from Trypanosoma cruzii and human cathepsins B and L (numbering according to the papain sequence). The initial alignment was produced using the PILEUP package (UWGCG, Daresbury, UK) and edited manually using the crystal structure of papain as a point of reference. This alignment was scored using the AMAS software package (Barton, Oxford, UK); human and mouse lymphopain form one subgroup, CP5, papain, cruzipain, cathepsins L and B from another. The alignment was scored at a threshold setting of 6; positions boxed in red are identically conserved in all the sequences analysed. Those boxed in blue show identity within one subgroup only. Positions boxed in green show similarity in one or both of the subgroups. The probable final residue of the signal peptide and first residue of the mature forms are indicated by arrowheads labelled S and M, respectively. Two potential N-linked glycosylation sites in human and murine lymphopain are indicated by open purple circles. Propeptide residues normally conserved in the ERFNIN subgroup 15 of family C1 peptidases 1 are indicated by open yellow circles. The active site residues are marked by filled black circles. The normally invariant Gly 23 position is indicated by an open blue circle. The positions of the C-termini of mature cathepsin B 46 and cruzipain, 47 resulting from C-terminal processing, are shown by arrowheads labelled B and Z, respectively. The mRNA from human lymphopain encodes for a protein of 376 residues, five more than the murine enzyme. The native cruzipain sequence extends for an additional 118 amino acids beyond those shown in the alignment. Sequence information was obtained from the following sources: papain, SwissProt PAPAFCARPA; cruzipain, SwissProt CYSPFTRYCR; human cathepsin B; SwissProt CATBFHUMAN; human cathepsin L; 5 CP5, EMBL L36205. The murine lymphopain sequence data are available from GenBank under accession number AF014941.
Continued also display 69% identity. This degree of identity is somewhat lower than normally observed for species variants within this family. However the degree of nucleotide similarity and the Zoo blot analysis argue strongly that the murine cDNA we have cloned is indeed the homologue of human lymphopain.
Structural features of human and murine lymphopain
There are a number of conserved residues in the propeptide (Figure 5d ) that place lymphopain in the ERFNIN subgroup of the C1 peptidases, 15 distinct from cathepsin B. We therefore predict that the conformation and function of the propeptide of lymphopain will be similar to those of related enzymes, forming a globular domain, and a segment that runs through the active site cleft in the opposite direction to that of a substrate, sterically hindering access of substrate. 16, 17 Lymphopain will thus presumably be activated by removal of the propeptide. Berti and Storer 2 have phylogenetically classified the ERFNIN subgroup of family C1 enzymes into three lineages: the plant lineage, a lineage consisting largely of protozoan enzymes (Ddis1) and the cathepsin L lineage, which also contains another mammalian enzyme, cathepsin S. Representatives of each lineage are aligned with human and mouse lymphopain in Figure 5d . Human lymphopain shows only low levels of identity with the mature enzyme sequences of any of these (29% with the plant enzyme papain, 32% with cruzipain from the parasitic protozoan Trypanosoma cruzii, and 29% with human cathepsin L). Thus, lymphopain may represent a novel lineage of the C1 peptidases, having diverged due to a different function. Further strength to this argument is provided by the novel insertion in the lymphopain sequence between residues 168 and 169 of papain, on the opposite side of the molecule to the active site. The only other enzymes with an insertion in this position are found in the slime mould Dictyostelium discoideum, one of which, CP5, is aligned with lymphopain in Figure 5d . The function of the insertion in the slime mould enzymes is thought to be to provide site(s) for phosphoglycosylation of certain serine residues. 18 The novel insertion, although present in the mouse sequence, does not demonstrate a high degree of identity with either the human enzyme (33%) or with the sequences from the slime mould enzymes.
All the cysteine residues in the sequence of mature papain are conserved in lymphopain, suggesting that all three of the disulphide bonds have been retained, and that the gross conformation of the enzymes is similar. Amino acids implicated in the active site chemistry of papain 19 are completely conserved in the sequence of human lymphopain. These include Cys 25 and His 159 (papain numbering; Figure 5d) is almost invariant among the C1 peptidases. Where this resi-due is substituted it leads to a profound change of specificity due to steric hindrance to entry of the substrate into the S1 pocket. 21, 22 The substitution Gly 23 → Cys in lymphopain may therefore be expected to lead to a greater degree of selectivity of peptide bond cleavage than is evident with papain.
Functional studies of lymphopain
Preliminary experiments were directed at determining the cysteine peptidase activities in lysates of Lpn-transfected and mock-transfected COS cells. Using Bz-Phe-Val-Arg-NHMec as substrate, these experiments demonstrated that the transfected cells had a higher specific activity (953 nM/min/10 6 cells) than mock-transfected cells (527 nM/min/10 6 cells) at pH 5.5 in the presence of 4 mM cysteine. Using the other substrates tested (see below) and a pH of 7.2 instead of 5.5, the difference in activity between the transfected and mock-transfected cells was not as great (results not shown). The enzymatic activity of Lpn was then examined using lymphopain-programmed rabbit reticulocyte lysates (Figure 6a ). The human lymphopain mRNA cell-free translation product was screened for activity against Bz-Phe-Val-Arg-NHMec, which is cleaved by most members of the C1 peptidase family. The highest activity was found at pH 5.5 (not shown), so these conditions were chosen for further study. The activities of human lymphopain cell-free translation product and a control were determined against this substrate, in the presence and absence of cysteine and E64. The experiment was repeated with new cell-free translation products, and in both experiments the activity of the Lpn sample was higher than the control in the presence of cysteine. E64 inhibited the activity found in the lymphopain sample, but not that in the control sample. The results of one of the two experiments are shown in Figure 6b . These results are consistent with the presence of a C1 family peptidase in the lymphopain sample, but not in the control, and we conclude that we were measuring the activity of human lymphopain.
The propeptide of the C1 family peptidases acts as an inhibitor of the enzyme, and must be removed for the expression of full activity. Conditions in vitro that lead to activation of some of these enzymes include incubation at acidic pH with or without pepsin. 23, 24 However preincubation of the human Lpn cell-free translation product under these conditions failed to generate increased activity (results not shown). It is known that the proforms of some C1 family peptidases can express limited activity against small substrates, 23 and that the active site cysteine remains accessible to small organic molecules much as amidase substrates and alkylating reagents such as E64, despite the presence of the propeptide. 25, 26 Perspective Clearly, further work is required to elucidate the mechanism of activation of Lpn and the full spectrum of its activity. However the in vitro demonstration of enzyme activity associated with lymphopain, coupled to its restriction to the cytotoxic/natural killer compartment, raises the possibility that it plays a role in cell killing. Our cloning of the murine homologue of lymphopain will facilitate testing of this possibility through creation of targeted mutations in transgenic mice. Such an approach has proved invaluable in the dissection of the cellular functions of the granzymes, granule-associated serine proteases which have been implicated in cell killing (a) 35S-methionine-labelled coupled transcription translation reactions of sense (lymphopain) and antisense (control) human lymphopain containing pBluescript subclones were fractionated by SDS PAGE and autoradiographed. The lymphopain-specific product is arrowed and numbers on the right are in kilodaltons. Parallel reactions were used for assaying enzymatic activity of cell-free translation products against an amidase substrate (b). The products of cell-free translation of lymphopain mRNA were assayed using Z-Phe-Val-ArgNHMec at pH 5.5 and 37°C, as described in the Materials and methods section. Continuous-rate assays were used to record the level of activity in the buffer, then following addition of 4 mM cysteine, and finally after inactivation of a papain-like enzymes with 10 M E64.
(see . Granzymes have also been suggested as playing a role in number of other lymphocyte-associated processes 27 including extravasation and migration of mature T cells. Granzyme A has been shown to cleave several extracellular matrix proteins in vitro and granzyme B inhibits adhesion, and consequently growth of tumour cell lines. Granzyme B expression has also been documented in murine multipotential FDCP-mix A4 cells 33 and in mobilised CD34-positive cells. 34 Our own preliminary results (not shown) suggest that lymphopain is also expressed in both these cell types, possibly suggesting that some components of granzyme and lymphopain regulation or function may be shared.
Experimental procedures
Cloning and sequencing
Differential hybridisation/screening analysis was performed essentially as described by Davis. 35 Briefly 32 P-labelled singlestranded first strand KG-1a cDNA was hybridised in solution against excess microsomal or total K562 mRNA (rot 1/2 = ෂ3 × 10 3 ). Unhybridised cDNA was selected using hydroxyapatite chromatography and subjected to another round of hybridisation. This probe was used to screen KG-1a cDNA libraries prepared in gt 10 by established procedures. Libraries were estimated to contain 1-3 × 10 5 independent clones. 35, 36 5Ј and 3Ј RACE (rapid amplification of cDNA ends) was performed using the Clontech Marathon cDNA amplification kit according to the manufacturer's instructions (Clontech, Palo Alto, CA, USA). Genomic P1 clones were obtained through sequential PCR-based screening of clonal pools (Genome Systems, St Louis, MO, USA). DNA sequencing of KG-1a cDNA clones was performed using M13 subclones and the chain termination method and analysed by denaturing PAGE and subsequent autoradiography. Direct sequencing of PCR-derived products and genomic clones, as well as verification sequencing of DNA constructs, was performed using cycle sequencing and an automated ABI (Foster City, CA, USA) DNA sequencer. DNA sequences were analysed using software packages available at Seqnet, Daresbury and Barton.
Isolation and blotting of cellular RNA and DNA
Total cellular RNA was isolated from tissues or cell lines using the guanidinium isothiocyanate procedure of Chirgwin et al, 37 or the one-step acid guanidinium/phenol/chloroform method 38 when dealing with smaller numbers of cells. Polyadenylated (poly (A) + ) RNA was isolated as previously described 39 by one cycle of chromotography on oligo (dT)-cellulose (Collaborative Research). Poly A + or total cellular RNA was prepared for electrophoresis by denaturation in 50% formamide, 2.2 M formaldehyde and 20 mM phosphate, pH 7.6, and run through 1.1% agarose gels, essentially as described. 40 Gels were transferred in 20 × SSC to charged nylon membranes (Amersham, Little Chalfont, UK) and hybridised with ␣-32 P-dCTP-oligolabelled probes as described 41 except that the hybridisation buffer was supplemented with 0.2% PVP, 0.2% Ficoll, 0.1% SDS and 0.2 mg/ml sonicated salmon sperm DNA. After overnight hybridisation at 65°C, membranes were washed in 0.5-0.1 × SSC, 0.1% SDS for 1 h and autoradiographed or phosphoimaged (Molecular Dynamics, Sunnyvale, CA, USA). For isolation of genomic DNA, cells were lysed in 100 mM TrisHCl, pH 8.0, 50 mM NaCl, 12.5 mM EDTA, 0.2% SDS and digested overnight at 37°C with 100 g/ml proteinase K. DNA was extracted with phenol, ethanol-precipitated and resuspended in distilled H 2 O. DNA was limit-digested with restriction enzymes according to the supplier's instructions and electrophoresed on 0.8% agarose 1 × TAE gels prior to transfer in 0.4 M NaOH on to Hybond N + membranes (Amersham). Membranes were hybridised with ␣-32 P-oligolabelled probes as described for RNA blots or with ␥-32 P-end-labelled oligomers.
Chromosomal localisation by FISH
Genomic DNA from (PAC/P1/cosmid) clones were labelled with biotin-14-d-ATP (Gibco, Paisley, UK) by nick translation as described previously. 42 Probes were hybridised to normal human metaphase chromosomes at 42°C for 2 h and stringency washed in 0.4 × SSC at 70°C for 2 min. Probe signal was detected with FITC-conjugated avidin and amplified with FITC-conjugated anti-avidin (Vector, Peterborough, UK). Chromosome bands were identified by DAPI staining. Probe signals were scored in 20 metaphase spreads using a Zeiss (Oberkochen, Germany) Axiophot microscope equipped with epi-fluorescence and a triple band pass filter. Digital images were obtained with a high resolution CCD camera (Photometrics, Tucson, AZ, USA) and Smartcapture software (Digital Scientific, Cambridge, UK).
Haemopoietic cells
Fractionation of peripheral blood: 40 ml of heparinised peripheral blood from two normal volunteers was used for the study. 5 mls were centrifuged for 20 min at 800 g and the buffy coat was retained (fraction 1). The remaining 35 ml were diluted v/v in HBBS, layered on Lymphoprep (Nycomed, Oslo, Norway) and centrifuged for 30 min at 600 g. A mononuclear fraction was obtained (fraction 4), the Lymphoprep was discarded and the cell pellet centrifuged again for 20 min at 200 r.p.m. which resulted in a lymphocyte-depleted buffy coat. Half of the latter was treated with NH 4 Cl to lyse the red blood cells (fraction 2) and the other half resuspended in Hank's (fraction 3). All four fractions were washed three times in Hank's prior to the molecular studies. Cytospin preparations were made and stained with May-Grü nwald-Giemsa to estimate the cellular components on each fraction. The cell composition in the four fractions is given in Figure 2 . In order to obtain a T cell-depleted fraction, 30 × 10 6 normal blood mononuclear cells were resuspended in 10 ml of RPMI-1640 and foetal calf serum and incubated with 10 ml of 1% sheep erythrocytes in RPMI-1640 medium for 10 min at 37°C. Thereafter, they were centrifuged for 5 min at 600 g and incubated for 3 h at 4°C. The cell pellet was carefully resuspended in RPMI-1640, layered on Lymphoprep and centrifuged for 30 min at 600 g producing an interface layer, which was depleted of cells forming rosettes with sheep erythrocytes (Erosette negative cells or non-T cells) and a pellet containing the E-rosette-positive fraction (T cells). The E-rosette negative fraction contained B cells and monocytes and was free of T cell contamination as assessed by staining with CD2 and CD3 whilst the E-rosette fraction was CD2 + (99%+). Lymphocytes from two normal volunteers were enriched for CD4
+ and CD8 + subpopulations by using magnetic sorting with CD4 and CD8 microbeads, according to the manufacturer's instructions. The purity of the fractions was assessed by testing them with monoclonal antibodies against CD4 and CD8. Mononuclear cells from patient blood was obtained with consent, according to the methods described above. FACS analysis was carried out using standard procedures on a Becton Dickinson (San Francisco, CA, USA) FACS analyser equipped with LYSIS II software. Established haemopoietic cell lines were cultured in RPMI 1640, supplemented with 10% FCS and 4 mM glutamine, at 37°C, in 5% CO 2 in a highly humidified incubator.
Enzymatic assays
For cell-free translation human lymphopain cDNA was subcloned downstream of the T3 RNA polymerase promoter in pBluescript (Stratagene, La Jolla, CA, USA). This plasmid was used to programme a coupled transcription-translation rabbit reticulocyte lysate system (TNT, Promega Biotec, Madison, WI, USA) according to the manufacturer's intructions. Sample reactions were monitored by labelling with 35 S-methionine (Amersham) and subsequent SDS PAGE analysis. Continuousrate fluorimetric assays were employed to investigate the amidase activity present in cell-free translation products of human lymphopain mRNA and controls, essentially as previously described, 43 using a Perkin-Elmer (Norwalk, CT, USA) LS50B fluorimeter coupled to a personal computer running the FLU-SYS 44 software package. The result of cell-free translation (5 l) was incubated in the fluorimeter cuvette with 20 mM Mes, pH 5.5, containing 1 mM Na 2 EDTA and 0.05% Triton X-100, and the fluorimetric substrate (5 M) (final volume 3 ml), at 37°C. The steady-state increase in fluorescence was recorded before cysteine base was added in a negligible volume from a stock solution, to a concentration of 4 mM. After a few minutes, the new steady-state rate of product formation was stable. E64 was then added to a concentration of 10 M. A few more minutes were allowed for the development of the new steady state, which was recorded. Biochemical reagents were purchased from Sigma (Poole, UK). The fluorimetric substrates for amidase activity Z-Phe-Arg-NHMec, Bz-Phe-ValArg-NHMec and Z-Arg-Arg-NHMec were purchased from Bachem (Bubendorf, Switzerland). Boc-Ala-Ala-Gly-NHMec was synthesized as described. 45 
